Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: A useful tool for patient risk stratification

European Journal of Endocrinology

Volumn 164, Issue 6, 2011, Pages 971-976

  Mian, Caterina ^a   Pennelli, Gianmaria ^a   Barollo, Susi ^a   Cavedon, Elisabetta ^a   Nacamulli, Davide ^a   Vianello, Federica ^a   Negro, Isabella ^a   Pozza, Giulia ^a   Boschin, Isabella Merante ^b   Pelizzo, Maria Rosa ^b   Rugge, Massimo ^a   Mantero, Franco ^a   Girelli, Maria Elisa ^a   Opocher, Giuseppe ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; METHIONINE; MOLECULAR MARKER; PROTEIN RET; THREONINE; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISTANT METASTASIS; FEMALE; FOLLOW UP; GENDER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SOMATIC MUTATION; THYROID MEDULLARY CARCINOMA; TUMOR VOLUME; CANCER SURVIVAL; CLINICAL ASSESSMENT TOOL; GENOTYPE PHENOTYPE CORRELATION; NECK DISSECTION; ONCOGENE; OUTCOME ASSESSMENT; RET GENE; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SEX DIFFERENCE; THYROIDECTOMY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, MEDULLARY; EXONS; FEMALE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-RET; RISK ASSESSMENT; ROC CURVE; SURVIVAL ANALYSIS; THYROID NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79957707824     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0079     Document Type: Article

References (22)

1. Leboulleux S, Baudin E, Travagli J & Schlumberger M. Medullary thyroid carcinoma. Clinical Endocrinology 2004 61 299-310. (doi:10.1111/j.1365- 2265.2004.02037.x)
2. Gharib H, McConahey WM, Tiegs RD, Bergstralh EJ, Goellner JR, Grant CS, van Heerden JA, Sizemore GW & Hay ID. Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970. Mayo Clinic Proceedings 1992 67 934-940.
3. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M & Wells SA Jr. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009 19 565-612. (doi:10.1089/thy.2008.0403)
4. Girelli ME, Nacamulli D, Pelizzo MR, De Vido D, Mian C, Piccolo M & Busnardo B. Medullary thyroid carcinoma: clinical features and long-term follow-up of seventy-eight patients treated between 1969 and 1986. Thyroid 1998 8 517-523. (doi:10.1089/thy.1998.8.517)
5. Dottorini ME, Assi A, Sironi M, Sangalli G, Spreafico G & Colombo L. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 1996 77 1556-1565. (doi:10.1002/(SICI)1097-0142(19960415)77:8〈1556:: AID-CNCR20〉3.0.CO;2-Y)
6. Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, Schlumberger M, Bigorgne JC, Dumontier P, Leclerc L, Corcuff B & Guilhem I. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. Clinical Endocrinology 1998 48 265-273. (doi:10.1046/j.1365-2265.1998.00392.x)
7. Joshi PP, Kulkarni MV, Yu BK, Smith KR, Norton DL, Van Veelen W, Höppener JW & Franklin DS. Simultaneous downregulation of CDK inhibitors p18(Ink4c) and p27(Kip1) is required for MEN2ARET-mediated mitogenesis. Oncogene 2007 26 554-570. (doi:10. 1038/sj.onc.1209811)
8. Cavalheiro BG & Rodrigues JC. Expression of MMP-2 and TIMP-2 in medullary thyroid carcinoma. Thyroid 2008 18 865-871. (doi:10.1089/thy.2007. 0412)
9. Buergy D, Weber T, Maurer GD, Mudduluru G, Medved F, Leupold JH, Brauckhoff M, Post S, Dralle H & Allgayer H. Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies. International Journal of Cancer 2009 125 894-901. (doi:10.1002/ijc.24462)
10. Uchino S, Noguchi S, Yamashita H, Sato M, Adachi M, Watanabe S, Ohshima A, Mitsuyama S, Iwashita T & Takahashi M. Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type. Japanese Journal of Cancer Research 1999 90 1231-1237.
11. Schilling T, Bürck J, Sinn HP, Clemens A, Otto HF, Höppner W, Herfarth C, Ziegler R, Schwab M & Raue F. Prognostic value of codon 918 (ATG/ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. International Journal of Cancer 2001 95 62-66. (doi:10.1002/1097-0215(20010120) 95:1〈62::AID-IJC1011〉3.0.CO;2-1)
12. Fugazzola L, Muzza M, Mian C, Cordella D, Barollo S, Alberti L, Cirello V, Dazzi D, Girelli ME, Opocher G, Beck-Peccoz P & Persani L. RET genotypes in sporadic medullary thyroid cancer: studies in a large Italian series. Clinical Endocrinology 2008 69 418-425. (doi:10.1111/j.1365-2265.2008.03218.x)
13. Dvorakova S, Vaclavikova E, Sykorova V, Vcelak J, Novak Z, Duskova J, Ryska A, Laco J, Cap J, Kodetova D, Kodet R, Krskova L, Vlcek P, Astl J, Vesely D & Bendlova B. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas. Molecular and Cellular Endocrinology 2008 284 21-27. (doi:10.1016/j.mce.2007.12.016)
14. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F, Miccoli P, Berti P, Pacini F & Pinchera A. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year followup study. Journal of Clinical Endocrinology and Metabolism 2008 93 682-687. (doi:10.1210/jc.2007-1714)
15. Moura MM, Cavaco BM, Pinto AE, Domingues R, Santos JR, Cid MO, Bugalho MJ & Leite V. Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. British Journal of Cancer 2009 100 1777-1783. (doi:10.1038/sj.bjc.6605056)
16. Tisell LE, Oden A, Muth A, Altiparmak G, Mõlne J, Ahlman H & Nilsson O. The Ki67 index a prognostic marker in medullary thyroid carcinoma. British Journal of Cancer 2003 89 2093-2097. (doi:10.1038/sj.bjc.6601453)
17. American Joint Committee on Cancer. The thyroid gland. In AJCC Cancer Staging Manual, 6th edn., pp 77-87. New York: Wiley-Liss, 2002.
18. Elisei R. Routine serum calcitonin measurement in the evaluation of thyroid nodules. Best Practice and Research. Clinical Endocrinology and Metabolism 2008 22 941-953. (doi:10.1016/j.beem.2008.09.008)
19. Giraudet AL, Al Ghulzan A, Aupérin A, Leboulleux S, Chehboun A, Troalen F, Dromain F, Lumbroso J, Baudin E & Schlumberger M. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. European Journal of Endocrinology 2008 158 239-246. (doi:10.1530/EJE-07-0667)
20. Meijer JA, Le Cessie S, van den Hout WB, Kievit J, Schoones JW, Romijn JA & Smit JW. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clinical Endocrinology 2010 72 534-542. (doi:10.1111/j.1365-2265.2009.03666.x)
21. Rugge M, Fassan M, Clemente R, Rizzardi G, Giacomelli L, Pennelli G, Mescoli C, Segat D & Rea F. Bronchopulmonary carcinoid: phenotype and long-term outcome in a singleinstitution series of Italian patients. Clinical Cancer Research 2008 14 149-154. (doi:10.1158/1078-0432.CCR-07-1631)
22. Faggiano A, Grimaldi F, Pezzullo L, Chiofalo MG, Caracò C, Mozzillo N, Angeletti G, Santeusanio F, Lombardi G, Colao A, Avenia N & Ferolla P. Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer. Endocrine-Related Cancer 2009 16 225-231. (doi:10.1677/ERC-08- 0152)